Login / Signup

Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.

Jordi Rodon AhnertSilvia DamianMuhammad FurqanJesús García-DonasHiroo ImaiAntoine ItalianoIben SpanggaardMakoto UenoTomoya YokotaMaria Luisa VeroneseNatalia OliveiraXin LiAidan GilmartinMichael SchafferLipika Goyal
Published in: Nature medicine (2024)
Keyphrases
  • study protocol
  • phase iii
  • signaling pathway
  • clinical trial
  • phase ii
  • newly diagnosed